Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Shonan iPark Set for Expansion as It Looks to Establish Profile as Regenerative Medicine Hub
October 16, 2024
-
REGULATORY Japan Political Parties Push Varied Pharma Policies as Election Campaign Kicks Off
October 15, 2024
-
ORGANIZATION EFPIA Chief Sees Positive Signal from Japan Policymakers, Calls for Consistency
October 11, 2024
-
REGULATORY Kisunla to Follow Same Rules as Leqembi in Pricing and Post-Launch Review
October 10, 2024
-
BUSINESS Pfizer Curbs Supply of Avastin Biosimilar, 2 Others Hit by Knock-On Effect
October 9, 2024
-
BUSINESS Supply Curb Hits New Generic of Hirudoid Lotion, Demand Driven by Elective Care?
October 8, 2024
-
BUSINESS J&J Eyes Double-Digit Growth in Japan Pharma Biz from 2027, 50 Approvals by 2029
October 7, 2024
-
REGULATORY Panel OKs Withdrawal Rule for Conditional Nod, 2-Year Extension for Pediatric Data Protection towards PMD Act Amendment
October 4, 2024
-
ORGANIZATION Policy Veterans’ Group Proposes Special Drug Price Rule for Antibiotics
October 3, 2024
-
REGULATORY New Health Minister Eager to Build Pharma Ecosystem in Japan
October 3, 2024
-
REGULATORY New Finance Minister Vows Full Discussions with MHLW on FY2025 Revision
October 3, 2024
-
REGULATORY New Cabinet Might Move the Needle in Off-Year Debate: Industry Exec
October 2, 2024
-
REGULATORY Japan’s New PM Eyes Social Security Reform as Cabinet Unveiled
October 2, 2024
-
REGULATORY Takamaro Fukuoka Named as New Health Minister
October 1, 2024
-
REGULATORY Japan Compiles First Biosimilar Roadmap
October 1, 2024
-
ACADEMIA Pharmacies, Hospitals Scrambling to Address New LLP Coverage Rule, Concerns Swirl Around Misuse
October 1, 2024
-
REGULATORY Ishiba Elected as New LDP Leader, Hopes Are High for Medical and Pharma Policies
September 30, 2024
-
REGULATORY MHLW to Publish Info Necessary for Driving Biosimilar Switches in FY2025
September 27, 2024
-
REGULATORY Kisunla Subject to Prior Pricing Review as It Follows Leqembi’s Footsteps
September 26, 2024
-
REGULATORY Japan Approves Lilly’s Kisunla, Eisai’s ALS Med, Gilead’s Trodelvy, and Lots More
September 25, 2024
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…